Edges in Network
| Network | GSE16446_egf1520 - GSE16446 - SiGN-BN HC+Bootstrap |
| Network Description | Predicting the efficacy of anthracyclines in breast cancer (BC) patients: The results of the TOP trial |
| Node | ATP2A2 |
| Upstream (Parents) |
|---|
| (<<) ACTB → ATP2A2 |
| (<<) ADAM15 → ATP2A2 |
| (<<) CFL1 → ATP2A2 |
| (<<) GAPDH → ATP2A2 |
| (<<) HPCAL1 → ATP2A2 |
| (<<) MCL1 → ATP2A2 |
| (<<) PPP1CA → ATP2A2 |
| (<<) PTPN11 → ATP2A2 |
| (<<) RARG → ATP2A2 |
| (<<) RAVER1 → ATP2A2 |
| (<<) RHOA → ATP2A2 |
| (<<) RPS16 → ATP2A2 |
| (<<) SHC1 → ATP2A2 |
| (<<) TAGLN2 → ATP2A2 |
| (<<) TPP1 → ATP2A2 |
| (<<) TUBB2C → ATP2A2 |
| (<<) UBE2N → ATP2A2 |
| Downstream (Children) |
|---|
| ATP2A2 → ABCF1 (>>) |
| ATP2A2 → ANKDD1A (>>) |
| ATP2A2 → ANXA2 (>>) |
| ATP2A2 → ATN1 (>>) |
| ATP2A2 → BAALC (>>) |
| ATP2A2 → DDR1 (>>) |
| ATP2A2 → EPHA1 (>>) |
| ATP2A2 → EPHB2 (>>) |
| ATP2A2 → FOXB1 (>>) |
| ATP2A2 → FOXO3 (>>) |
| ATP2A2 → FZD3 (>>) |
| ATP2A2 → GNA12 (>>) |
| ATP2A2 → GNAI3 (>>) |
| ATP2A2 → GNB5 (>>) |
| ATP2A2 → GRK5 (>>) |
| ATP2A2 → HLA-G (>>) |
| ATP2A2 → HSPB1 (>>) |
| ATP2A2 → KLF6 (>>) |
| ATP2A2 → KPNA1 (>>) |
| ATP2A2 → LOC642031 (>>) |
| ATP2A2 → LRP5 (>>) |
| ATP2A2 → MAN2A2 (>>) |
| ATP2A2 → MAP2K3 (>>) |
| ATP2A2 → MAPKAPK5 (>>) |
| ATP2A2 → MSN (>>) |
| ATP2A2 → MTMR6 (>>) |
| ATP2A2 → MVK (>>) |
| ATP2A2 → NAB2 (>>) |
| ATP2A2 → NFATC3 (>>) |
| ATP2A2 → NR3C1 (>>) |
| ATP2A2 → PAK4 (>>) |
| ATP2A2 → PDIA3 (>>) |
| ATP2A2 → PGK1 (>>) |
| ATP2A2 → PIM1 (>>) |
| ATP2A2 → PITPNA (>>) |
| ATP2A2 → PPIF (>>) |
| ATP2A2 → PRKAB1 (>>) |
| ATP2A2 → PRKCD (>>) |
| ATP2A2 → RAP1A (>>) |
| ATP2A2 → RPL22L1 (>>) |
| ATP2A2 → SLC45A3 (>>) |
| ATP2A2 → ST3GAL1 (>>) |
| ATP2A2 → STK11 (>>) |
| ATP2A2 → STX12 (>>) |
| ATP2A2 → THOC4 (>>) |
| ATP2A2 → TMEFF2 (>>) |
| ATP2A2 → TNRC18 (>>) |
| ATP2A2 → TUBA1A (>>) |
| ATP2A2 → VCP (>>) |
| ATP2A2 → VPS37B (>>) |
